Department of Gynecologic Endocrinology and Reproductive Medicine-Medical University of Vienna, Vienna, Austria.
J Sex Med. 2011 Aug;8(8):2361-9. doi: 10.1111/j.1743-6109.2011.02311.x. Epub 2011 May 19.
Cross-sex hormone therapy (CSHT) is known to lead to alterations in the serum lipid profile. However, the available reports in the literature are problematic, because of methodological limitations.
To assess changes in the fasting serum lipid profile during CSHT, including long-term follow-up.
Retrospective chart analysis of all 89 male-to-female (MtF) and 80 female-to-male (FtM) transsexuals who underwent standard CSHT at the Department of Gynecologic Endocrinology of the Medical University of Vienna (university hospital, tertiary care center), from 1995 to 2009.
The results of the lipid profile were analyzed, including triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and the TC-to-HDL ratio, at the time of treatment initiation (time point "0") and at 3, 12, 24, and 60 months after the start of CSHT.
The mean age of patients about to commence CSHT was 35.7 ± 11.4 years (MtF) and 26.0 ± 6.3 years (FtM). For MtF transsexuals, consistent follow-up for 24 and 60 months was available in 83 (93.3%) and 58 (65.2%) patients, respectively; for FtM transsexuals, follow-up was available in 57 (71.3%) and 39 (48.8%) patients, respectively. When testing for an association between the lipid parameters and the time after treatment initiation, significant increases for TG (P < 0.001), TC (P = 0.021), and HDL (P = 0.001) were found for MtF transsexuals, whereas TG, TC, and LDL (P < 0.001) increased and HDL (P < 0.001) decreased in FtM patients.
Both MtF and FtM transsexuals experience alterations in the serum lipid profile because of CSHT, with the changes in FtM patients possibly more relevant in terms of atherogenesis.
已知跨性别激素治疗（CSHT）会导致血清脂质谱发生变化。然而，由于方法学上的限制，文献中的现有报告存在问题。
评估 CSHT 过程中空腹血清脂质谱的变化，包括长期随访。
对 1995 年至 2009 年期间在维也纳医科大学妇科内分泌科（大学医院，三级保健中心）接受标准 CSHT 的 89 名男性到女性（MtF）和 80 名女性到男性（FtM）跨性别者进行回顾性图表分析。
分析脂质谱的结果，包括甘油三酯（TG）、总胆固醇（TC）、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）和 TC/HDL 比值，在治疗开始时（时间点“0”）和 CSHT 开始后 3、12、24 和 60 个月。
即将开始 CSHT 的患者的平均年龄为 35.7±11.4 岁（MtF）和 26.0±6.3 岁（FtM）。对于 MtF 跨性别者，分别有 83（93.3%）和 58（65.2%）名患者可进行 24 和 60 个月的持续随访；对于 FtM 跨性别者，分别有 57（71.3%）和 39（48.8%）名患者可进行随访。在测试脂质参数与治疗后时间之间的关联时，发现 MtF 跨性别者的 TG（P<0.001）、TC（P=0.021）和 HDL（P=0.001）显著增加，而 FtM 患者的 TG、TC 和 LDL（P<0.001）增加，HDL（P<0.001）减少。
CSHT 会导致 MtF 和 FtM 跨性别者的血清脂质谱发生变化，FtM 患者的变化在动脉粥样形成方面可能更为相关。
